Results 11 to 20 of about 97,726 (142)

JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level [PDF]

Therapeutics and Clinical Risk Management, 2014
Roberta Lanzillo,1 Raffaele Liuzzi,2 Luca Vallefuoco,3 Marcello Moccia,1 Luca Amato,1 Giovanni Vacca,1 Veria Vacchiano,1 Giuseppe Portella,3 Vincenzo Brescia Morra1 1Neurological Sciences Department, Federico II University, 2Institute of Biostructure and
Lanzillo R, Liuzzi R, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia Morra V   +8 more
doaj   +10 more sources

High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis. [PDF]

Mult Scler J Exp Transl Clin, 2018
We performed a cross-sectional study in 123 Chinese multiple sclerosis patients residing in Hong Kong to evaluate their anti-John Cunningham virus status using STRATIFY JCV DxSelect assays.
Lau A, Qiu W, Kermode A, Au C, Ng A, Wong A, Ma SH, Au L, Ma K, Ip B, Mok V.   +10 more
europepmc   +4 more sources

Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis [PDF]

Arquivos de Neuro-Psiquiatria, 2018
Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists
Luciana Prats Branco, Tarso Adoni, Samira Luisa Apostolos-Pereira, Joseph Bruno Bidin Brooks, Eber Castro Correa, Carlos Augusto Damasceno, Audred Cristina Biondo Eboni, Leticia Fezer, Paulo Diniz da Gama, Marcus Vinicius Magno Goncalves, Sidney Gomes, Anderson Kuntz Grzesiuk, Maria Fernanda Mendes, Rogerio Rizo Morales, Andre Muniz, Monica Fiuza Koncke Parolin, Maria Lucia Vellutini Pimentel, Marlise de Castro Ribeiro, Gutemberg Augusto Cruz dos Santos, Henry Koiti Sato, Simone Batista Scherpenhuijzen, Claudio Scorcine, Fabio Siquineli, Nise Alexandra de Carvalho Sousa, Daniel Lima Varela, Tereza Cristina Avila Winckler, Yara Dadalti Fragoso   +26 more
doaj   +5 more sources

Favorable Response to Mirtazapine in John Cunningham Virus-related Gray Matter Lesion in a Patient with Human Immunodeficiency Virus. [PDF]

Cureus, 2019
Mirtazapine has recently emerged as a promising agent for the treatment of progressive multifocal leukoencephalopathy (PML). While there is no Class I evidence for its use, numerous case reports have illustrated mirtazapine’s efficacy.
Alwehaibi AI, AlJaber MI, Nahrir S.
europepmc   +5 more sources

John Cunningham virus T-antigen expression in anal carcinoma. [PDF]

Cancer, 2011
AbstractBACKGROUND:Anal carcinoma is thought to be driven by human papillomavirus (HPV) infection through interrupting function of cell regulatory proteins such as p53 and pRb. John Cunningham virus (JCV) expresses a T‐antigen that causes malignant transformation through development of aneuploidy and interaction with some of the same regulatory ...
Ramamoorthy S, Devaraj B, Miyai K, Luo L, Liu YT, Boland CR, Goel A, Carethers JM.   +7 more
europepmc   +7 more sources

Humoral response to John Cunningham virus during pregnancy in multiple sclerosis. [PDF]

Multiple Sclerosis and Related Disorders, 2018
BACKGROUND Pregnancy induces an immunosuppressive state in the mother to ensure immunological acceptance of the foetus. Impairment of cell-mediated immune responses may render the mother susceptible to intracellular pathogens.
M. Saraste, S. Atula, K. Hedman, S. Hurme, A. Jalkanen, M. Sneck, H. Surcel, A. Maghzi, L. Airas   +8 more
semanticscholar   +7 more sources

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

European Journal of Neurology, 2017
Background and purposeInfection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause.
Z. L. V. Kempen, C. Leurs, A. D. Vries, A. Vennegoor, T. Rispens, M. Wattjes, J. Killestein   +6 more
semanticscholar   +6 more sources

Structural vaccinology, molecular simulation and immune simulation approaches to design multi-epitopes vaccine against John Cunningham virus.

Microbial Pathogenesis
The JCV (John Cunningham Virus) is known to cause progressive multifocal leukoencephalopathy, a condition that results in the formation of tumors. Symptoms of this condition such as sensory defects, cognitive dysfunction, muscle weakness, homonosapobia ...
Muhammad Suleman, T. Khan, Hadiqa Ejaz, S. Maroof, Abdulrahman Alshammari, Norah A. Albekairi, Haji Khan, Yasir Waheed, Abbas Khan, Dongqing Wei, Sergio Crovella   +10 more
semanticscholar   +8 more sources

Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis.

Seminars in Arthritis and Rheumatism, 2015
OBJECTIVE The John Cunningham virus (JCV) is a generally benign and asymptomatic polyomavirus. Due to an association of the anti-integrin agent natalizumab with progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), a ...
D. Borie, J. Kremer
semanticscholar   +5 more sources

Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment. [PDF]

Biomedicines
Background/Objectives: Multiple sclerosis (MS) is a disease characterized by demyelination and axonal damage of the central nervous system. Despite the observed benefits, highly effective treatment (HET)-based therapy has adverse effects, which include ...
García S, García-Martell A, Quiñones-Aguilar S, Sauri-Suárez S, Téllez González MA, García-Castillo G, Suárez-Cuenca JA, Toledo-Lozano CG, Mondragón Terán P, Alcaraz-Estrada SL.   +9 more
europepmc   +2 more sources